Publications by authors named "Giuseppe Cuccorese"

Article Synopsis
  • The study focused on creating a scoring system called the OCA response score (ORS) to predict how individuals with primary biliary cholangitis (PBC) will respond to the treatment using obeticholic acid (OCA).
  • Data were collected from two large cohorts in Italy to derive and validate the score, which includes various clinical factors both before and after six months of treatment.
  • The scoring system demonstrated good predictive ability for treatment response, which could help healthcare providers customize therapies for patients with PBC more effectively.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the safety and effectiveness of obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) who have advanced cirrhosis.
  • Factors such as male sex, INR levels, Child-Pugh score, MELD score, and bilirubin levels were linked to non-response and serious adverse events (SAEs) in patients taking OCA.
  • The findings suggest that careful baseline evaluations, especially bilirubin levels above 1.4 mg/dl, are essential in determining which patients can safely benefit from OCA treatment.
View Article and Find Full Text PDF

Lemierre's syndrome (LS) is a "forgotten" condition characterized by septic thrombophlebitis of the jugular vein that follows an otolaryngological infection. Fusobacterium necrophorum is the aetiological agent responsible for the syndrome in adolescents and young adults whereas in older people even common bacteria are involved. Complications arise from spreading of septic emboli distally, to the brain, lungs, bones and internal organs everywhere in the body.

View Article and Find Full Text PDF

Background And Objectives: The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in genotype 3 (GT3) with compensated and is recommended in decompensated cirrhosis. Real-life results with SOF/VEL are limited.

View Article and Find Full Text PDF

Background: Sustained virological response (SVR12) rates at 12 weeks after treatment for HCV-infected patients with decompensated cirrhosis are used when referring to those with moderate functional impairment, while few data are available for those with more severe impairment. The use of the cirrhosis staging system proposed by D'Amico might provide new insights on timing for antiviral therapy.

Methods: We investigated efficacy (SVR12), safety, and post-treatment variations in clinical and laboratory parameters in 2612 patients with advanced fibrosis (n=575) or cirrhosis (n=2037).

View Article and Find Full Text PDF

Background: Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or dual therapy in comparison to those who were deferred.

View Article and Find Full Text PDF

Background & Aims: Different prevalence of favourable IL28BCC genotype have been reported in studies performed in different countries around the world. Data on distribution of IL28B genotypes in healthy Italian subjects are lacking.

Methods: Studies on prospectively collected untreated chronic HCV-infected Italian patients led to conflicting results.

View Article and Find Full Text PDF